Kymera Perspectives

Powering Possibility Through Oral Medicines with Biologics-like Profiles

With our unique approach and deep drug discovery expertise, we are advancing a pipeline of oral small molecule degrader programs addressing high value targets in key immuno-inflammatory signaling pathways to create unprecedented possibilities for patients. Our first-in-human data for KT-621, our investigational, first-in-class, oral STAT6 degrader, unlocks game changing potential for the industry and for patients. Hear from Nello Mainolfi, PhD, Founder, President and CEO, on how this milestone moment reinforces Kymera’s strategy and ability to advance revolutionary oral medicines with biologics-like profiles.